Azura Ophthalmics nets $20m

Azura Ophthalmics Ltd, an Israeli developer of therapies for Meibomian gland dysfunction and related eye diseases, has raised $20 million in financing.

To view this content, you need to sign in.


You should only be asked to sign in once. Not the case? Click here


Register now to access this content and more for free.

Share this